Results 161 to 170 of about 82,941 (302)
RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment
Precision Medical Sciences, EarlyView.This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run +7 more
wiley +1 more source
Precision Medical Sciences, EarlyView.Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik +4 more
wiley +1 more source
Precision Radiation Oncology, EarlyView.Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu +4 more
wiley +1 more source
Targeting the untargetable? Nodal expression in TNBC [PDF]
Cell Cycle, 2016 Eric D, Young, Danny R, Welch
openaire +2 more sources
Natural Products as Modulators of ABC Transporters in Breast Cancer
Phytotherapy Research, EarlyView.ABSTRACT Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple‐negative breast cancer (TNBC), continues to hinder effective therapy.
Yoganishalini Sagadevan +2 more
wiley +1 more source
Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
Asia-Pacific Journal of Clinical Oncology, EarlyView.Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski +6 more
wiley +1 more source
Targeting hexokinase 2 to induce breast cancer cell senescence
British Journal of Pharmacology, EarlyView.Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof +8 more
wiley +1 more source
AKT inhibition improves OS in TNBC [PDF]
Nature Reviews Clinical Oncology, 2020 openaire +2 more sources
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
The Organoid Decade: Leveraging 3D Patient-Derived Organoids to Bridge the Translational Gap in Triple-Negative Breast Cancer: A Systematic Review. [PDF]
CellsSani J, Yi B, Xi Y.
europepmc +1 more source